US20210024594A1 - Therapeutic Agent for Psoriasis - Google Patents

Therapeutic Agent for Psoriasis Download PDF

Info

Publication number
US20210024594A1
US20210024594A1 US16/967,919 US201916967919A US2021024594A1 US 20210024594 A1 US20210024594 A1 US 20210024594A1 US 201916967919 A US201916967919 A US 201916967919A US 2021024594 A1 US2021024594 A1 US 2021024594A1
Authority
US
United States
Prior art keywords
psoriasis
amino acid
acid sequence
peptide
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/967,919
Other languages
English (en)
Inventor
Katsuto Tamai
Takashi SHIMBO
Takehiko Yamazaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Osaka University NUC
StemRIM Inc
Original Assignee
Osaka University NUC
StemRIM Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osaka University NUC, StemRIM Inc filed Critical Osaka University NUC
Assigned to StemRIM Inc. reassignment StemRIM Inc. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: YAMAZAKI, TAKEHIKO
Assigned to OSAKA UNIVERSITY reassignment OSAKA UNIVERSITY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SHIMBO, Takashi, TAMAI, KATSUTO
Publication of US20210024594A1 publication Critical patent/US20210024594A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • compositions for the prevention and/or treatment of psoriasis which comprise a fragment peptide of the high mobility group box 1 (HMGB1) protein.
  • Psoriasis is a chronic skin disease characterized by inflammation of the skin and abnormal proliferation of keratinocytes. Although the cause of psoriasis is not yet fully elucidated, the disease is thought to develop by genetic factors plus various external factors (infectious diseases, stress, drugs, etc.). In recent years, it has been shown that abnormalities in immune function are involved.
  • corticosteroids for the treatment of psoriasis, corticosteroids, vitamin D3 derivatives, immunosuppressants (such as cyclosporin), vitamin A derivatives (retinoids), biological preparations (e.g., anti-TNF- ⁇ antibodies, anti-IL-17A antibodies, and anti-IL-17 receptor A antibodies), and such have been used; however, there are cases where sufficient effect cannot be obtained.
  • immunosuppressants such as cyclosporin
  • vitamin A derivatives retinoids
  • biological preparations e.g., anti-TNF- ⁇ antibodies, anti-IL-17A antibodies, and anti-IL-17 receptor A antibodies
  • An objective of the present application is to provide novel pharmaceuticals that are effective in the treatment of psoriasis.
  • an HMGB1 fragment peptide having a specific amino acid sequence exhibits an effect of suppressing erythema, scaling (desquamation), and thickening (infiltration) of the skin in an animal model of psoriasis. Accordingly, the present application provides pharmaceutical compositions for the prevention and/or treatment of psoriasis, which comprise the specific HMGB1 fragment peptide.
  • a pharmaceutical composition for the prevention and/or treatment of psoriasis comprising a substance described in any of the following (a) to (c) (herein below referred to as substance A):
  • a method of preventing and/or treating psoriasis comprising administering an effective amount of substance A to a subject.
  • a method of suppressing a skin symptom selected from the group consisting of erythema, thickening, and scaling or desquamation in a patient with psoriasis comprising administering an effective amount of substance A to the patient.
  • Substance A for use in the prevention and/or treatment of psoriasis.
  • Substance A for use in the suppression of a skin symptom selected from the group consisting of erythema, thickening, and scaling or desquamation in a patient with psoriasis.
  • substance A in the manufacture of a medicament for the prevention and/or treatment of psoriasis.
  • substance A in the manufacture of a medicament for the suppression of a skin symptom selected from the group consisting of erythema, thickening, and scaling or desquamation in a patient with psoriasis.
  • FIG. 1 presents photographs of the back of mice used as a criterion for scoring erythema.
  • the numbers (0-4) above the photographs represent the scores corresponding to the degree of erythema (no symptoms: 0, mild: 1, moderate: 2, severe: 3, and extremely severe: 4).
  • FIG. 2 presents photographs of the back of mice used as a criterion for scoring scaling.
  • the numbers (0-4) above the photographs represent the scores corresponding to the degree of scaling (no symptoms: 0, mild: 1, moderate: 2, severe: 3, and extremely severe: 4).
  • FIG. 3 is a graph showing the change in the PASI score after the start of imiquimod application.
  • the PASI score on the 5th day from the start of imiquimod application (Day 5) was significantly different between the control group (see “IMQ/saline”) and the HMGB1 peptide (1-44) administration group (see “IMQ/1-44”) (*p ⁇ 0.05).
  • the PASI score is shown as a missing value because the value of measuring skin thickness could not be obtained due to a problem with the measuring instrument.
  • FIG. 4 presents graphs showing the changes in the erythema, scaling, and thickening scores after the start of imiquimod application.
  • the thickening score is shown as a missing value because the value of measuring skin thickness could not be obtained due to a problem with the measuring instrument.
  • FIG. 5 presents photographs of the back of the mice on the 5th day from the start of imiquimod application.
  • FIG. 6 presents graphs showing the expression levels of the inflammatory cytokines in the skin on the 5th day from the start of imiquimod application.
  • FIG. 7 is a graph showing the change in the PASI score after the start of imiquimod application.
  • FIG. 8 presents graphs showing the expression levels of the inflammatory cytokines in the skin on the 5th day from the start of imiquimod application.
  • compositions for the prevention and/or treatment of psoriasis which comprise an HMGB1 fragment peptide comprising the amino acid sequence described in SEQ ID NO: 1.
  • psoriasis includes, but is not limited to, plaque psoriasis, psoriasis arthropica (psoriatic arthritis), guttate psoriasis, psoriatic erythroderma, and generalized pustular psoriasis.
  • the psoriasis of the present application is plaque psoriasis.
  • plaque psoriasis The main symptoms of plaque psoriasis include “erythema”, where the skin becomes red, “thickening (also referred to as infiltration)”, where the skin is raised, “scaling”, where excessively grown keratin is piled up like scabs, and “desquamation”, where the scaling comes off.
  • pharmaceutical composition is used interchangeably with “medicament”, “drug”, or “pharmacological composition”.
  • the pharmaceutical compositions of the present application are used for suppressing a skin symptom selected from the group consisting of erythema, thickening (infiltration), and scaling or desquamation in patients with psoriasis.
  • a skin symptom selected from the group consisting of erythema, thickening (infiltration), and scaling or desquamation in patients with psoriasis.
  • the pharmaceutical compositions of the present application can be used to suppress these skin symptoms in patients with plaque psoriasis.
  • an HMGB1 fragment peptide comprising the amino acid sequence described in SEQ ID NO: 1 refers to a peptide consisting of a portion of the HMGB1 protein and comprising the amino acid sequence described in SEQ ID NO: 1.
  • Such a peptide can be obtained as genetic recombinants by incorporating DNA encoding the peptide into an appropriate expression system or can be synthesized artificially.
  • examples of the HMGB1 protein include, but are not limited to, proteins comprising the amino acid sequence described in SEQ ID NO: 2 and proteins encoded by DNA comprising the nucleotide sequence described in SEQ ID NO: 3.
  • peptides that comprise an amino acid sequence with one or more amino acid residues modified (substituted, deleted, inserted, or added) in the amino acid sequence described in SEQ ID NO: 1 and that are functionally equivalent to an HMGB1 fragment peptide comprising the amino acid sequence described in SEQ ID NO: 1 can be used instead of or in combination with an HMGB1 fragment peptide comprising the amino acid sequence described in SEQ ID NO: 1.
  • peptides include, but are not limited to, peptides of the following i) to iv), and peptides of the following i) to iv) and having the effect of preventing and/or treating psoriasis:
  • a peptide comprising an amino acid sequence in which one or more amino acids (e.g., one to ten, one to nine, one to eight, one to seven, one to six, one to five, one to four, one to three, or one or two) have been substituted, deleted, inserted, or added in the amino acid sequence described in SEQ ID NO: 1;
  • one or more amino acids e.g., one to ten, one to nine, one to eight, one to seven, one to six, one to five, one to four, one to three, or one or two
  • a peptide consisting of an amino acid sequence in which one or more amino acids (e.g., one to ten, one to nine, one to eight, one to seven, one to six, one to five, one to four, one to three, or one or two) have been substituted, deleted, inserted, or added in the amino acid sequence described in SEQ ID NO: 1;
  • one or more amino acids e.g., one to ten, one to nine, one to eight, one to seven, one to six, one to five, one to four, one to three, or one or two
  • a peptide comprising an amino acid sequence having about 80% or more, for example, about 85% or more, about 90% or more, about 91% or more, about 92% or more, about 93% or more, about 94% or more, about 95% or more, about 96% or more, about 97% or more, about 98% or more, or about 99% or more sequence identity with the amino acid sequence described in SEQ ID NO: 1; and
  • a peptide consisting of an amino acid sequence having about 80% or more, for example, about 85% or more, about 90% or more, about 91% or more, about 92% or more, about 93% or more, about 94% or more, about 95% or more, about 96% or more, about 97% or more, about 98% or more, or about 99% or more sequence identity with the amino acid sequence described in SEQ ID NO: 1.
  • an effective amount of the peptide of the present application or a pharmaceutical composition comprising the peptide (hereinafter, referred to as the peptide or such) is administered to a subject for the treatment or prevention of the diseases or symptoms described herein.
  • An effective amount as used herein refers to an amount sufficient for the treatment or prevention of the diseases or symptoms as described herein.
  • Treatment in the present application includes, but is not limited to, alleviation, delay, blockade, improvement, remission, cure, and complete cure.
  • Prevention in the present application includes, but is not limited to, alleviation, delay, and blockade.
  • Subjects in the present application include, without limitation, mammals, birds, fish, and such. Mammals include, but are not limited to, humans and non-human animals, for example, humans, mice, rats, monkeys, pigs, dogs, rabbits, hamsters, guinea pigs, horses, sheep, and whales. In the present application, the term “subject” is used interchangeably with “patient”, “individual”, and “animal”.
  • the site of administration of the peptide or such of the present application there is no limitation on the site of administration of the peptide or such of the present application, and the peptide or such of the present application can exert its effect when administered to any site, such as a site where a symptom of psoriasis appears or a site nearby, a site different from these sites (a site other than these sites), a site separated from a site where a symptom of psoriasis appears, a site distal from a site where a symptom of psoriasis appears, or a site distal and ectopic to a site where a symptom of psoriasis appears.
  • the peptide or such of the present application can also exert its effect when administered to any tissue, such as a tissue different from a tissue where a symptom of psoriasis appears (the skin, joint, and such), a tissue separated from a tissue where a symptom of psoriasis appears, a tissue distal from a tissue where a symptom of psoriasis appears, or a tissue distal and ectopic to a tissue where a symptom of psoriasis appears.
  • tissue such as a tissue different from a tissue where a symptom of psoriasis appears (the skin, joint, and such), a tissue separated from a tissue where a symptom of psoriasis appears, a tissue distal from a tissue where a symptom of psoriasis appears, or a tissue distal and ectopic to a tissue where a symptom of psoriasis appears.
  • Methods of administering the peptide or such of the present application include, but are not limited to, oral administration and parenteral administration.
  • Methods of parenteral administration include, but are not limited to, intravascular (intra-arterial, intravenous, and such), intramuscular, subcutaneous, intradermal, intraperitoneal, nasal, pulmonary, and transdermal administrations.
  • the peptide or such of the present application can also be administered systemically or locally (e.g., subcutaneously, intradermally, or to the skin surface, eyeball or palpebral conjunctiva, nasal mucosa, oral and gastrointestinal mucosa, vaginal and endometrial mucosa, or injured site) by injection administration, for example, intravenous injection, intramuscular injection, intraperitoneal injection, and subcutaneous injection.
  • injection administration for example, intravenous injection, intramuscular injection, intraperitoneal injection, and subcutaneous injection.
  • the administration method can be appropriately selected according to the age and symptoms of a patient.
  • the dose can be selected, for example, from the range of 0.0000001 mg to 1000 mg per kilogram of body weight per administration.
  • the dose can be selected, for example, from the range of 0.00001 to 100000 mg/body for a patient.
  • administering cells secreting the peptide of the present application or gene therapy vectors into which DNA encoding the peptide has been inserted they can be administered so that the amount of the peptide is within the above range.
  • the pharmaceutical compositions in the present application are not limited to these dosages.
  • compositions of the present application can be formulated according to conventional methods (e.g., Remington's Pharmaceutical Science, latest edition, Mark Publishing Company, Easton, U.S.A.), and may contain pharmaceutically acceptable carriers and additives together.
  • pharmaceutically acceptable carriers and additives include, but are not limited to, surfactants, excipients, coloring agents, perfumes, preservatives, stabilizers, buffers, suspending agents, isotonizing agents, binding agents, disintegrants, lubricants, fluidity-promoting agents, and flavoring agents.
  • Other commonly used carriers can also be used as appropriate.
  • Specific examples include, light anhydrous silicic acid, lactose, crystalline cellulose, mannitol, starch, carmellose calcium, carmellose sodium, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinylacetal diethylaminoacetate, polyvinylpyrrolidone, gelatin, medium-chain fatty acid triglycerides, polyoxyethylene hydrogenated castor oil 60, white sugar, carboxymethyl cellulose, cornstarch, and inorganic salts.
  • a cream containing 5% imiquimod (Beselna Cream 5%, manufactured by Mochida Pharmaceutical Co., Ltd.) was used.
  • Imiquimod is represented as IMQ in the drawings corresponding to the Examples of this application.
  • a peptide consisting of amino acid residues 1-44 of the human-derived HMGB1 protein (SEQ ID NO: 1) was chemically synthesized by a solid-phase method.
  • the HMGB1 fragment peptide is referred to as the HMGB1 peptide (1-44) and is expressed as an abbreviation “1-44” in the drawings corresponding to the Examples.
  • C57BL/6 mice (7-week-old, female, body weight about 20 g) were prepared, and the hair on the back was removed.
  • the cream containing 5% imiquimod was applied to the dorsal skin of the mice at a dose of 1.25 g/animal/day (62.5 mg/animal/day as imiquimod) once a day for four days.
  • the day when imiquimod was first applied is represented as “the 1st day of the start of imiquimod application (Day 1)”, and the next day onward is represented as “the Xth day from the start of imiquimod application (Day X)”. That is, the last day that imiquimod was applied was the 4th day from the start of imiquimod application (Day 4), and no application was performed on the 5th day from the start of imiquimod application (Day 5).
  • the test substance was administered by injecting an HMGB1 peptide (1-44) solution, which has been adjusted to a concentration of 1 ⁇ g/ ⁇ l with saline as the vehicle, into the vein at a dose of 100 ⁇ l/day (5 mg/kg/day as the peptide dose) for three days from the 1st day of the start of imiquimod application (Day 1).
  • saline was injected into the vein at a dose of 100 ⁇ l/day for three days from the 1st day of the start of imiquimod application.
  • the degree of the symptoms of psoriasis on the dorsal skin of the mice was evaluated by the PASI score for five days from the 1st day of the start of imiquimod application.
  • the PASI score was calculated by quantifying the degree of each of (a) erythema, (b) scaling (desquamation), and (c) thickening (infiltration) of skin using five stages, [no symptoms: 0 points, mild: 1 point, moderate: 2 points, severe: 3 points, and extremely severe: 4 points], and summing up the values of (a), (b), and (c) (minimum 0 points-maximum 12 points).
  • the erythema score was determined by using the photographs of the back of mice shown in FIG. 1 as a criterion for each score and visually comparing them with the condition of the back of the mice to be evaluated.
  • the scaling score was determined by using the photographs of the back of mice shown in FIG. 2 as a criterion for each score and visually comparing them with the condition of the back of the mice to be evaluated.
  • the thickening score was determined as follows: Two measurement sites were determined on the back of the mice, the skin was pinched and its thickness was measured with a caliper, and the average value from the two sites was recorded daily as the skin thickness (mm).
  • Quantification was carried out by giving 0 points when the value of skin thickness of each day relative to the skin thickness on the 1st day of the start of imiquimod application (before application) was less than 1.1, 1 point when the value was 1.1 or more to less than 1.3, 2 points when the value was 1.3 or more to less than 1.5, 3 points when the value was 1.5 or more to less than 1.7, and 4 points when the value was 1.7 or more.
  • FIG. 3 and FIG. 4 respectively show the changes in the PASI score and the scores for each item of erythema, scaling, and thickening up to the 5th day from the start of imiquimod application (see “IMQ/saline” for the control group and “IMQ/1-44” for the HMGB1 peptide (1-44) administration group).
  • the PASI score as well as the erythema, scaling, and thickening scores tended to increase as the days passed in both the control group and the HMGB1 peptide (1-44) administration group.
  • all these scores in the HMGB1 peptide (1-44) administration group were lower than those in the control group.
  • the PASI score in the HMGB1 peptide (1-44) administration group was significantly lower than that in the control group on the 5th day from the start of imiquimod application.
  • the photographs of the back of the mice on the 5th day from the start of imiquimod application are shown in FIG. 5 (see “IMQ/saline” for the control group and “IMQ/1-44” for the HMGB1 peptide (1-44) administration group).
  • FIG. 6 shows the expression levels of the inflammatory cytokines in the skin on the 5th day from the start of imiquimod application (see “IMQ/saline” for the control group and “IMQ/1-44” for the HMGB1 peptide (1-44) administration group).
  • the expression levels of all of IL-6, IL-17F, and IL-22 in the HMGB1 peptide (1-44) administration group were lower than those in the control group.
  • the drugs were prepared and the psoriasis model mice were produced in the same way as Example 1.
  • the peptides were administered in the same way as Example 1 except that the number of mice was changed to six in both the HMGB1 peptide (1-44) administration group and the control group.
  • the degree of the symptoms of psoriasis on the dorsal skin of the mice was evaluated by the PASI score for four days from the 1st day of the start of imiquimod application.
  • the PASI score was calculated in the same manner as Example 1.
  • the dorsal skin of the mice was collected, mRNA was extracted from the skin, and the expression levels of the inflammatory cytokines (IL-1 ⁇ , IL-6, IL-17A, IL-17F, and IL-22), which are known to be involved in the pathogenesis of psoriasis, were analyzed by quantitative PCR.
  • IL-1 ⁇ , IL-6, IL-17A, IL-17F, and IL-22 inflammatory cytokines
  • FIG. 7 shows the change in the PASI score up to the 4th day from the start of imiquimod application (see “IMQ/saline” for the control group and “IMQ/1-44” for the HMGB1 peptide (1-44) administration group). From the 2nd day from the start of imiquimod application, the PASI score increased as the days passed in both the control group and the HMGB1 peptide (1-44) administration group. However, the PASI score in the HMGB1 peptide (1-44) administration group was lower than that in the control group ( FIG. 7 ). The result indicates that the administration of the HMGB1 peptide (1-44) suppressed the skin symptoms in the psoriasis model mice.
  • FIG. 8 shows the expression levels of the inflammatory cytokines in the skin on the 5th day from the start of imiquimod application (see “IMQ/saline” for the control group and “IMQ/1-44” for the HMGB1 peptide (1-44) administration group).
  • the expression levels of all of IL-11 ⁇ , IL-6, IL-17A, IL-17F, and IL-22 in the HMGB1 peptide (1-44) administration group were lower than those in the control group.
  • compositions comprising the peptide of the present application are expected to provide great benefits to patients with psoriasis who cannot obtain a sufficient effect with existing therapeutics.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
US16/967,919 2018-02-08 2019-02-07 Therapeutic Agent for Psoriasis Abandoned US20210024594A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018-020687 2018-02-08
JP2018020687 2018-02-08
PCT/JP2019/004330 WO2019156137A1 (ja) 2018-02-08 2019-02-07 乾癬の治療薬

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2019/004330 A-371-Of-International WO2019156137A1 (ja) 2018-02-08 2019-02-07 乾癬の治療薬

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/817,084 Continuation US20220380420A1 (en) 2018-02-08 2022-08-03 Therapeutic Agent for Psoriasis

Publications (1)

Publication Number Publication Date
US20210024594A1 true US20210024594A1 (en) 2021-01-28

Family

ID=67549733

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/967,919 Abandoned US20210024594A1 (en) 2018-02-08 2019-02-07 Therapeutic Agent for Psoriasis
US17/817,084 Pending US20220380420A1 (en) 2018-02-08 2022-08-03 Therapeutic Agent for Psoriasis

Family Applications After (1)

Application Number Title Priority Date Filing Date
US17/817,084 Pending US20220380420A1 (en) 2018-02-08 2022-08-03 Therapeutic Agent for Psoriasis

Country Status (4)

Country Link
US (2) US20210024594A1 (de)
EP (1) EP3750553A4 (de)
JP (1) JP7386455B2 (de)
WO (1) WO2019156137A1 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11298403B2 (en) 2017-12-01 2022-04-12 StemRIM Inc. Therapeutic agent for inflammatory bowel disease

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2571230C2 (ru) 2008-04-30 2015-12-20 Дженомикс Ко., Лтд. Способ сбора функциональных клеток in vivo с высокой эффективностью
RU2599448C2 (ru) 2009-10-28 2016-10-10 Дженомикс Ко., Лтд. Средства для стимуляции регенерации тканей путем привлечения мезенхимных стволовых клеток и/или плюрипотентных стволовых клеток костного мозга в кровь
MX2019008949A (es) 2017-01-27 2019-10-07 Stemrim Inc Agente terapeutico para cardiomiopatia, infarto al miocardio antiguo e insuficiencia cardiaca cronica.
CN113423466A (zh) * 2018-10-25 2021-09-21 国立大学法人大阪大学 软骨病症的治疗剂
WO2021215375A1 (ja) * 2020-04-20 2021-10-28 塩野義製薬株式会社 Ｈｍｇｂ１部分ペプチドを含有する製剤
WO2024005133A1 (ja) * 2022-06-30 2024-01-04 国立大学法人大阪大学 半月板の治療薬

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1569684A4 (de) * 2002-11-20 2006-08-02 Critical Therapeutics Inc Verwendung vonhmgb-fragmenten als entzündungshemmende mittel
WO2007011606A2 (en) * 2005-07-18 2007-01-25 Critical Therapeutics, Inc. USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS
EP2703487B1 (de) * 2011-04-26 2018-06-27 Genomix Co., Ltd. Peptide zur induktion der regenerierung von gewebe und verwendung davon
SG11201503215XA (en) 2012-10-25 2015-06-29 Genomix Co Ltd Novel method for treating spinal cord injury using hmgb1 fragment
MX361259B (es) 2012-10-25 2018-11-30 Univ Osaka Uso de un fragmento de peptido hmgb1 para el tratamiento del infarto al miocardio.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11298403B2 (en) 2017-12-01 2022-04-12 StemRIM Inc. Therapeutic agent for inflammatory bowel disease

Also Published As

Publication number Publication date
US20220380420A1 (en) 2022-12-01
EP3750553A4 (de) 2022-01-12
WO2019156137A1 (ja) 2019-08-15
EP3750553A1 (de) 2020-12-16
JPWO2019156137A1 (ja) 2021-01-28
JP7386455B2 (ja) 2023-11-27

Similar Documents

Publication Publication Date Title
US20220380420A1 (en) Therapeutic Agent for Psoriasis
US11298403B2 (en) Therapeutic agent for inflammatory bowel disease
AU671835B2 (en) The use of complement inhibitors for the preparation of a pharmaceutical for the prophylaxis and therapy of inflammatory intestinal and skin disorders as well as purpura
US9629895B2 (en) Method for prevention or treatment of intractable inflammatory bowel disease
BRPI0617664B1 (pt) Uso de um anticorpo que reconhece a il-6 para a produção de uma composição farmacêutica para tratar o enfarte do miocárdio ou suprimir a remodelagem ventricular esquerda depois do enfarte do miocárdio
WO2018186480A1 (ja) 線維性疾患の治療薬
JP2007500741A (ja) 一時的処置のための短い半減期を有するｃ１インヒビター
US10548870B2 (en) Method for treating multiple sclerosis
KR20200108494A (ko) 근위축성 측삭 경화증 치료제
JP7406192B2 (ja) 線維症治療薬
LT96079A (en) Use of corticotropin-releasing factor for the manufacture of a medicaments
DE69737088T2 (de) Therapeutisches agens zur behandlung von fiv infektionen
CN108853483B (zh) 经修饰的胸腺素β4在治疗脑缺血再灌注损伤方面的用途
CN113827585B (zh) 艾地苯在治疗肢带型肌营养不良2g型中的应用
EP4070808A1 (de) Pharmazeutische zusammensetzung zur vorbeugung oder behandlung von morbus behcet und rheumatoider arthritis mit einem peptid oder mischung daraus als wirkstoff
US20080090766A1 (en) Preventive or therapeutic agents for diseases including interleukin-18 inhibitor as an active ingredient
KR100392225B1 (ko) 류머티스 관절염 치료용 프로디지오신 조성물
JP6654773B2 (ja) インターロイキン３６受容体アンタゴニスト欠損症の治療薬
AU2021466375A1 (en) Drug for treating fatty liver and non-alcoholic steatohepatitis
JP2024517025A (ja) 乾癬の治療のための方法
US20140121164A1 (en) Prevention of kidney injury or disease
TW202120116A (zh) 纖維肌痛症之治療藥或預防藥
US7655237B2 (en) Use of soluble CD14 for treatment of type 2 diabetes mellitus
JP2023094736A (ja) 疼痛治療薬
CN117771344A (zh) 西曲瑞克的应用

Legal Events

Date Code Title Description
AS Assignment

Owner name: STEMRIM INC., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:YAMAZAKI, TAKEHIKO;REEL/FRAME:053917/0846

Effective date: 20200828

Owner name: OSAKA UNIVERSITY, JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TAMAI, KATSUTO;SHIMBO, TAKASHI;REEL/FRAME:053918/0190

Effective date: 20200831

STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION